Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Michael Y. Choi, George F. Widhopf, Christina C.N. Wu, Bing Cui, Fitzgerald Lao, Anil Sadarangani, Joy Cavagnaro, Charles Prussak, Dennis A. Carson, Catriona Jamieson, Thomas J. Kipps

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

81 Citas (Scopus)

Resumen

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL.

Idioma originalInglés
Número de artículo549
Páginas (desde-hasta)S167-S169
PublicaciónClinical Lymphoma, Myeloma and Leukemia
Volumen15
N.ºS
DOI
EstadoPublicada - 1 jun. 2015
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2015 The Authors.

Huella

Profundice en los temas de investigación de 'Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1'. En conjunto forman una huella única.

Citar esto